



IMAPAC
IMAGINE YOUR IMPACT

5th Edition

BIOLOGICS

**WORLD
NORDICS 2024**

**FACILITATING THE
DEVELOPMENT AND
MANUFACTURING OF
HIGH QUALITY BIOLOGIC
DRUGS IN THE NORDICS
REGION!**

6th- 7th March 2024

Radisson Blu Scandinavia Hotel
Copenhagen, Denmark

5th Edition

BIOLOGICS

WORLD
NORDICS 2024

6th - 7th March 2024

Radisson Blu Scandinavia Hotel
Copenhagen, Denmark

200+ Attendees

100+ Organizations

30+ Expert Speakers

PROGRAM AGENDA

Contact

Ana Laxamana, Senior Business Development Manager
e: ana.laxamana@imapac.com | m: +65 6983 6132

Follow us



TABLE OF CONTENTS

- 1 Our Clients
- 2 2024 Sponsors | What Our Clients Say
- 3 Concept: 5th Annual Biologics World Nordic 2024
- 5 2024 Speakers
- 7 Agenda At A Glance
- 8 Conference Day 1
- 12 Conference Day 2
- 16 Poster Presentation
- 17 Event Highlight
- 18 Expected Audience Snapshot
- 19 Registration Form
- 20 Event Calendar 2024
- 24 About IMAPAC



OUR CLIENTS



AND MANY MORE..

2024 SPONSORS

SILVER SPONSORS

AsahiKASEI | **Siegfried**
BIOPROCESS

ASSOCIATE SPONSORS

 **cytiva** | **bioner**
your trusted life science partner

EXHIBITORS

Curida | **RE•FEYN**
WEIGHING MOLECULES WITH LIGHT

 **GTP Bioways**
CDMO
Continuum for biologics

SVAR
Answers in Life Science

ADVERTISERS

Novo Nordisk
Pharmatech A/S


novo nordisk®

5th Edition
BIOLOGICS
WORLD
NORDICS 2024

EVAXION
AI-Immunology

“ I find the conference very good and well organised. Good discussion. I enjoyed it. ”

EVAXION BIOTECH

“

Thank you for a great conference and for an excellent organization from your side. I enjoyed my attendance and had very many nice meetings and discussion. ”

TANGAVAX


BAVARIAN NORDIC

“ This meeting was a great opportunity to share meaningful conversation with companies based in the same geographic region. We could discuss our overlapping interests and common set of difficulties, sharing potential solutions and providing a fertile ground for collaboration. ”

BAVARIAN NORDIC

CONCEPT

BIOLOGICS WORLD NORDICS 2024

The Nordic region, which includes Denmark, Finland, Iceland, Norway, and Sweden, is home to a thriving biologics industry.

The biologics industry in the Nordic region is expected to continue growing in the coming years, driven by factors such as increasing investment in research and development, a focus on innovation and new technologies, and a growing demand for advanced therapies. With its strong research and development infrastructure, highly skilled workforce, and supportive regulatory environment, the region is well-positioned to remain a key player in the global biologics industry.

The Biologics World Nordics was launched in 2018 and was a resounding success. With over a 130 attendees covering more than 60% of the commercial, clinical and pre-clinical biologics manufacturers. IMAPAC managed to address some of the key issues that the industry in the region is facing.

The 5th Annual Biologics World Nordics 2024 will continue the legacy by bringing the decision makers to join the conference and clinical research strategies, exploring cost reduction, process optimization strategies to maintain competitiveness as well as leveraging opportunities for strategic partnerships and in- and out-licensing opportunities.



5th Edition

BIOLOGICS

WORLD

NORDICS 2024

WHO

C-Suites, Heads, Presidents, Directors, VPs, of R&D, Manufacturing, Bioprocessing, Upstream Processing, Downstream Processing, Quality Assurance & Control, Fill Finish, Packaging from biologics companies from Nordic and the rest of the world.

WHAT

Evaluate the latest strategies, technologies and solutions in building a technologically enhanced high-speed and resilient sensitive biologics through Nordic's clinical trials and markets.

WHY

As the popularity of highly targeted biologic drugs fuels a huge growth in the market, along with the lapsing patents of several foundational biologic drugs that promises to spur the biosimilars market which is poised to grow by \$31.40 bn during 2021-2025. 31.40 bn

Join the 5th Annual Biologics World Nordic 2024!

SPEAKERS 2024



Annika Ericsson
Director Preclinical Development,
CombiGene, Sweden



Annika Karlsson
Resin Sales Specialist,
Cytiva



Ashesh Kumar
CEO, Paras
Biophama, Finland



Bjorn Voldborg
Head of the National Biologics
Facility, DTU Bioengineering,
Denmark



Evelina Vagesjo
CEO, Ilya Pharma, Sweden



Fabio Rosa
Co-founder and Head of Research,
Asgard Therapeutics, Sweden



Huram Konjen
Chief Executive Officer,
Dianox, Denmark



Jens Kringelum
VP, AI & Innovation, Evaxion
Biotech, Denmark



Jette Asboe Lassen
CBO,
Bioneer



Julian Read
Chief Executive Officer,
Simris Group, Sweden



Laura Millichamp
Founder,
InsideReg, Switzerland



Liselotte Larsson
COO,
Cantargia, Sweden



Luiza Jedlina
CSO and co-founder,
Aptahem, Sweden



Marcus Larsson
CEO, Amniotics,
Sweden



Mathias Svahn
CEO, NextCell
Pharma, Sweden



Mats Lundgren
Vice President Research
and Development, Abera
Bioscience, Sweden

5th Edition

BIOLOGICS

WORLD
NORDICS 2024



Olaf Wegener

*Head of Research and Development,
Siegfried Hameln*



Pinar Carkci

*Product Manager,
Asahi Kasei Bioprocess*



Peter Holst

*Chief Science Officer,
Hervolution Therapeutics,
Associate Professor,
University of Copenhagen,
Denmark*



Rasmus Beedholm-Ebsen

*Senior Advisor - Life Science,
Invest in Denmark (Ministry
of Foreign Affairs of Denmark)*



Petter Bjorquist

CEO, VERIGRAFT, Sweden



Sara Mangsbo

*Professor in Antibody Drugs,
Uppsala University, Sweden*



Peter Ellmark

*Chief Science Officer,
Alligator Bioscience, Sweden*

AGENDA AT A GLANCE

Day 1 - 6 th March 2024	Day 2 - 7 th March 2024
Plenary Session: Innovations in Biologics in the Nordics Region	R&D and Clinical Trial Results for Nordics: Grown Biopharma for mAbs & Recombinant Proteins
Morning Tea Break, Exhibition Viewing & 1-1 Attendees Networking	
Upstream Advancements From Cell Line Development to Scale-Up in Bioprocessing and Innovative Therapies	Nordics Cell and Gene Therapy Pipeline & Solutions Showcase
Downstream Processing: Advances in Product Concentration and Purification	
Lunch Break, Exhibition Viewing & 1-1 Attendees Networking	
Downstream Processing: Advances in Product Concentration and Purification	Vaccine Pipeline & Technology Showcase
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendees Networking	
Roundtable Discussion: Opportunities in the Nordics Biologics Sector, Exploring Growth, Innovation, and Collaboration	Nordics Biologics Industry 2030
End of Conference Day 1	End of Conference Day 2

FOR SPEAKING OPPORTUNITIES, KINDLY CONTACT:

Caterin Sanggita,
 Conference Producer
 e: caterin.sanggita@imapac.com

CONFERENCE DAY 1

6th March 2024 | Copenhagen, Denmark

5th Annual Biologics World Nordics 2024 Day 1 [6 th March 2024]	
8:50	IMAPAC's Opening Address
8:55	Chairman's Opening Address Rasmus Beedholm-Ebsen, Senior Advisor - Life Science, Invest in Denmark (Ministry of Foreign Affairs of Denmark)
Plenary Session: Innovations in Biologics in the Nordics Region	
9:00	Nordics Leaders Panel Discussion: Innovations in Biologics in the Nordics Region <ul style="list-style-type: none">Recent advancements and breakthroughs in biologics medicines from the Nordics regionStrategies and regulations for long-term and equitable access to biologic medicines in the Nordics countriesCreating an innovation culture and driving research and development in biologics in the NordicsAccessing the right talent pool to meet the evolving needs of the biologics industry Moderated by: Ashesh Kumar, CEO, Paras Biopharma, Finland Panellists: Petter BJORQUIST, CEO, VERIGRAFT, Sweden Rasmus Beedholm-Ebsen, Senior Advisor - Life Science, Invest in Denmark (Ministry of Foreign Affairs of Denmark)
9:40	From Science to Cutting Edge Technology: Supporting Pharmaceutical Innovations in the Nordic Biotech Ecosystem <ul style="list-style-type: none">A 40-year perspective on the value of regionally available innovation enablersLessons learned as a Research and Technology Organization (RTO) supporting start-ups and early biotech in the NordicsOutlook on critical success parameters enabling innovation in biologics Jette Asboe Lassen, CBO, Bioneer
10:05	What are the Benefits and Obstacles of High-quality Manufacturing in the Nordic Region? <ul style="list-style-type: none">How does manufacturing in the Nordic region compare to the rest of the world?What is the importance of sustainability measures for biologic drug and vaccine manufacturing?What are the barriers to attracting manufacturing companies to the Nordic Regions? Rasmus Beedholm-Ebsen, Senior Advisor - Life Science, Invest in Denmark (Ministry of Foreign Affairs of Denmark)
10:30	Morning Tea Break, Exhibition Viewing & 1-1 Attendees Networking

CONFERENCE DAY 1

6th March 2024 | Copenhagen, Denmark

Upstream Advancements: From Cell Line Development to Scale-Up in Bioprocessing and Innovative Therapies	
11:00	<p>Engineering the Next Generation of CHO Cells for the Development and Manufacturing of Novel Therapeutic Proteins</p> <ul style="list-style-type: none">• CHO research in the Nordic countries• Glycoengineered CHO cells• Production of glycovariants of drug candidates <p>Bjorn Voldborg, Head of the National Biologics Facility, DTU Bioengineering, Denmark</p>
Downstream Processing: Advances in Product Concentration and Purification	
11:25	<p>Introducing Planova™ S20N, a Novel Superior Regenerated Cellulose Virus Removal Filter</p> <ul style="list-style-type: none">• Novel Planova filter—Planova S20N - using superior regenerated cellulose• Planova S20N does not require the Gold Particle Test (GPT)• Planova S20N shows higher throughput, robust virus removal capability, and stable protein filterability at higher operating pressures while achieving stable filtration over a wide range of solution conditions <p>Pinar Carkci, Product Manager, Asahi Kasei Bioprocess</p>
11:50	<p>Practical Strategies for Byproducts and Impurities Removal in Complex Formats of Biologics (e.g. ADCs, Peptibodies, scFv)</p> <ul style="list-style-type: none">• Practical strategies tailored for the unique characteristics of complex biologics• Exploration of novel and effective approaches to byproducts and impurities removal• In-depth analysis of crucial considerations in the development of purification processes for complex biologics <p>Ashesh Kumar, CEO, Paras Biopharma, Finland</p>
12:15	Lunch Break, Exhibition Viewing & 1-1 Attendees Networking
Downstream Processing: Advances in Product Concentration and Purification	
1:15	<p>Balancing Quality, Timing and Investments in CMC for Biologics</p> <ul style="list-style-type: none">• Finding the perfect CDMO• Planning and execution• Future perspectives <p>Liselotte Larsson, COO, Cantargia, Sweden</p>

CONFERENCE DAY 1

6th March 2024 | Copenhagen, Denmark

1:40	<p>Chromatography for the Diverse Antibody Pipeline</p> <ul style="list-style-type: none">• The diversity of antibody variants in today's pipeline presents unique challenges for purification• Purification platforms used for many monoclonal antibodies (mAbs) need to be adopted for antibody variants to simplify protocols and improve purity and yield• The safety and efficiency requirement of conventional mAb processes are key also for antibody variants• Strategies for purifying bispecific antibodies and antibody fragments having the molecule type and the impurity profile in mind <p>Annika Karlsson, Resins Sales Specialist, Cytiva</p>
2:05	<p>Personalised Tissue Engineering that will Revolutionise Future Medicine</p> <ul style="list-style-type: none">• Fully biological, personalised tissue-engineered transplants that do not necessitate immunosuppression• A unique first-in-man clinical trial is ongoing, where hitherto uncured chronic venous insufficiency is being targeted• Several multi-billion USD markets are waiting for VERIGRAFT's product portfolio <p>Petter BJORQUIST, CEO, VERIGRAFT, Sweden</p>
CDMO Showcase Session	
2:30	<p>Overcoming Challenges in Transferring a Sterile Biologics Drug Product to a CDMO</p> <ul style="list-style-type: none">• Ensuring quality and compliance in biomanufacturing• Adjusting manufacturing processes throughout the course of a site-to-site transfer• Fulfilling special requirements on container closure systems for biologics• Closing gaps in development data prior to the first GMP production• Transferring analytical methods for drug products and drug substances <p>Managing risk in the manufacturing process, from raw material sourcing to final product release</p> <p>Olaf Wegener, Head of Research & Development, Siegfried Hameln</p>

CONFERENCE DAY 1

6th March 2024 | Copenhagen, Denmark

2:55	Afternoon Tea Break, Exhibition Viewing & 1-1 Attendees Networking
	Roundtable Discussion: Opportunities in the Nordics Biologics Sector, Exploring Growth, Innovation, and Collaboration
3:30	[Table 1] Strategic R&D: Integrating Production and Manufacturability from the Start Facilitator: Bjorn Voldborg, Head of the National Biologics Facility, DTU Bioengineering, Denmark [Table 2] Future of Medicine: Personalised vs Scalable Facilitator: Hiram Konjen, Chief Executive Officer, Dianox, Denmark [Table 3] Navigating Regulatory Landscapes in the Nordic Biologics Sector for Sustainable Growth and Collaboration Facilitator: Laura Millichamp, Founder, InsideReg, Switzerland
4:00	Key Takeaway Sharing by the Roundtable Facilitator
4:15	Chairman Closing Remarks Rasmus Beedholm-Ebsen, Senior Advisor - Life Science, Invest in Denmark (Ministry of Foreign Affairs of Denmark)
4:20	End of Conference Day 1

CONFERENCE DAY 2

7th March 2024 | Copenhagen, Denmark

5th Annual Biologics World Nordics 2024 Day 2 [7 th March 2024]	
8:50	IMAPAC's Opening Address
8:55	Chairman's Opening Address Huram Konjen , <i>Chief Executive Officer, Dianox, Denmark</i>
R&D and Clinical Trial Results for Nordics – Grown Biopharma for mAbs & Recombinant Proteins	
9:00	A Novel RNA Aptamer Targets Exosite 2 on Thrombin, Offering a Potential Treatment for Systemic Inflammation through a Unique Mechanism) <ul style="list-style-type: none">• Thrombin plays a vital role in coagulation and inflammation, making it a crucial point for therapeutic intervention that could significantly alter disease progression• RNA aptamers are a potent therapeutic option due to their high specificity and ability to target key proteins involved in disease pathways, such as thrombin• Preclinical studies have demonstrated Apta-1's promising efficacy and safety profiles, indicating its potential as an effective treatment for systemic inflammation with a unique mechanism of action Luiza Jedlina , <i>CSO and co-founder, Aptahem, Sweden</i>
9:25	ADAC™: A Novel Antibody-Based Drug Delivery Platform for Targeted Delivery of Synthetic Cargo in Era of Precision Immunotherapy <ul style="list-style-type: none">• Development of a humanised binder and tag allows for rapid drug cargo loading on antibodies with affinities in pM range ensuring stable drug complex formation• Development of a CD40 agonist bispecific protein design with the ADAC™ technology in place, shows excellent production yields both in transient production tests and from the generated stable cell line (>8g/l) ready for GMP production• Antibody-mediated cargo internalization and subsequent CD8+ T cell expansion/anti-tumour activity displays the possibility of cargo endosomal escape and effector functions induced by the ADAC™ technology Sara Mangsbo , <i>Professor in Antibody Drug, Uppsala University, Sweden</i>
9:50	Next-Generation ADC Payloads from Cyanobacteria <ul style="list-style-type: none">• A patented platform to produce ready-to-conjugate payloads produced in cyanobacteria• Microcystins as a lead programme with an extensive pipeline of other novel compounds• Scalable, safe, efficient, and sustainable production Julian Read , <i>Chief Executive Officer, Simris Group, Sweden</i>
10:15	Morning Tea Break, Exhibition Viewing & 1-1 Attendees Networking

CONFERENCE DAY 2

7th March 2024 | Copenhagen, Denmark

Nordics Cell and Gene Therapy Pipeline & Solutions Showcase	
10:45	<p>Amniotics Voyage: Taking an ATMP from Idea, through GMP, to Clinic</p> <ul style="list-style-type: none">• R&D (tissue-specific amniotic fluid MSC)• Facility, eQMS, and manufacturing• Phase 1b clinical trial (viral lower respiratory tract infections)• Way forward (lung transplantation) <p>Marcus Larsson, CEO, Amniotics, Sweden</p>
11:10	<p>Long Term Efficacy of a Single Cell Therapy Infusion to Delay Disease Progression in Type-1 Diabetes</p> <ul style="list-style-type: none">• Off-the-shelf mesenchymal stromal cell therapy for autoimmune disease• ProTrans is a patented platform technology for robust manufacturing of potent drug• Disease altering effect of a single infusion with a fixed dose of ProTrans <p>Mathias Svahn, CEO, NextCell Pharma, Sweden</p>
11:35	<p>Advancements in Gene Therapy for Chronic Pain: A New Innovative Approach</p> <ul style="list-style-type: none">• CombiGene: pioneering the Nordic gene therapy landscape• Revolutionising chronic pain treatment with novel gene therapy• Positive pre-clinical data and peptide-driven development <p>Annika Ericsson, Director Preclinical Development, CombiGene, Sweden</p>
12:00	Lunch Break, Exhibition Viewing & 1-1 Attendees Networking
Vaccine Pipeline & Technology Showcase	
1:00	<p>A New Mucosal Vaccine Platform</p> <ul style="list-style-type: none">• The importance of mucosal vaccination to prevent airborne infections• How the Abera Outer Membrane Vesicle vaccine platform can be used to design new vaccines rapidly• Data on efficacy, immunogenicity and safety for a number of vaccine candidates <p>Mats Lundgren, Vice President Research and Development, Abera Bioscience, Sweden</p>
1:25	<p>Personalised Cancer Vaccines: Levering hERVs as Vaccine Targets to Overcome Limitations in Low-mutational Cancers</p> <ul style="list-style-type: none">• Many cancer types are not suitable targets for traditional personalised cancer vaccines due to the low number of mutations• Human endogenous retroviruses constitute a novel type of cancer vaccine target to treat cancers with a low mutational burden• hERV burden stratifies patients treated with immunotherapy in low mutational burden cancers• Preclinical PoC has been obtained for personalised cancer vaccines targeting hERVs <p>Jens Kringelum, VP, AI & Innovation, Evaxion Biotech, Denmark</p>

CONFERENCE DAY 2

7th March 2024 | Copenhagen, Denmark

1:50	<p>Human Endogenous Retroviruses (HERVs) as Near Ubiquitous Targets in Late-stage Human Cancers and Cellular Senescence, Targets that are Necessary for Promoting Malignant Phenotypes and Cancer Survival</p> <ul style="list-style-type: none">• HERVs stand out among dark genome antigenic elements in that several have preserved the structural features of their infectious ancestors• This integrity can be used to develop Vectored Virus-like-vaccine (VLVs) approaches that can break tolerance and promote effective anticancer therapy by active immunisation• VLVs are being developed for human trials in cancer and neurodegenerative diseases <p>Peter Holst, Chief Science Officer, Hervolution Therapeutics, Associate Professor, University of Copenhagen, Denmark</p>
2:15	<p>Afternoon Tea Break, Exhibition Viewing & 1-1 Attendees Networking</p>
	<p>Nordics Biologics Industry 2030</p>
2:45	<p>Unleashing the Potential of Aptamers</p> <ul style="list-style-type: none">• The world's most powerful library with 10^{60} compounds• AI-generated aptamers to advance beyond SELEX limitations• Binding to difficult protein targets <p>Huram Konjen, Chief Executive Officer, Dianox, Denmark</p>
3:10	<p>Harnessing Cell Fate Reprogramming to Develop the Next Leap Forward in Cancer Immunotherapy</p> <ul style="list-style-type: none">• Poor immunogenicity of tumours underlies intrinsic resistance to available cancer immunotherapies• Conventional dendritic cell type 1 (cDC1) is a rare and powerful subset of dendritic cells critical to initiate antitumor immunity and response to available immunotherapies• Pre-clinical PoC has been demonstrated for AT-108, a novel cancer immunotherapy based on in-vivo reprogramming of tumour cells into immunogenic cDC1s to orchestrate anti-tumour immunity <p>Fabio Rosa, Co-founder and Head of Research, Asgard Therapeutics, Sweden</p>

CONFERENCE DAY 2

7th March 2024 | Copenhagen, Denmark

3:35	<p>emilimogene sigiulactibac: First Clinical Assets from the ILP-Platform in Topical and Oral Formulations</p> <ul style="list-style-type: none">• Many immuno-active proteins act locally and transiently - not suited for drug development as biologics or gene therapy• Drug delivery from lactic acid bacteria for topical and oral administration• Update on current programs and trials <p>Evelina Vagesjo, CEO, Ilya Pharma, Sweden</p>
4:00	<p>Building on Clinical Success – Developing Neo-X-Prime™ a Third Generation CD40 Agonist</p> <ul style="list-style-type: none">• Why targeting CD40 can be a gamechanger in immuno-oncology• Phase 2 clinical data from CD40 MAb mitazalimab in pancreatic cancer• The next generation: Neo-X-prime™ design rationale, structure, and translational data <p>Peter Ellmark, Chief Science Officer, Alligator Bioscience, Sweden</p>
4:25	<p>Chairman Closing Remarks Huram Konjen, Chief Executive Officer, Dianox, Denmark</p>
4:30	End of Conference

5th Edition

BIOLOGICS

WORLD
NORDICS 2024

POSTER PRESENTATION



 Copenhagen, Denmark

 6TH - 7TH March 2024

Discover Innovations:

**Biopharma Poster
Presentation**

REGISTER NOW



EVENT HIGHLIGHT

200+
Expected Attendees

The only event that brings Nordic biologics sector to the global forefront! Meet key decision makers from Nordic's top biologics biopharma companies with representations from Manufacturing, Quality, R&D, Supply Chain & Logistics and more!

100+
Key Organizations

Discover new partnership with both Nordic's key and emerging biologics players.

30+
Expert Speakers

Presentations from the companies in Nordic region on the latest R&D strategies, manufacturing technologies, co-development opportunities, and session dedicated to showcase session on cancer immunotherapies and cell & gene therapy research.

20+
Case Studies

Including insights on the latest innovation on the R&D Strategies, innovation in upstream and downstream processing, cost modeling, automation, and choosing single use vs continuous vs stainless steel.

48+
Hours of Networking

Interact with the decision makers from biologics, vaccines and cell & gene therapy companies from Nordic region to exchange information, build connections and opportunities. You can book your 1-1 meetings prior to the conference and keep in touch after the conference through the conference app, Swapcard.

EXPECTED AUDIENCE SNAPSHOT



By Geography

50%

Nordic

20%

Europe

18%

USA

12%

Asia

By Profile

50%

Nordics Biopharma

20%

International & Big Pharma

15%

CDMOs, CMOs and CROs

10%

Governments, Academic & Research Institutes

10%

Technology & Service Providers

By Job Title

15%

CEO/GM/MD

25%

VP/Director/Heads

20%

R&D

20%

Manufacturing/Process Development

15%

Business Development & Marketing

5%


Others

Registration Form

Pricing Packages	Limited Super (By 31st Oct 2023)	Limited Special (By 30th Nov 2023)	Early Bird (By 2nd Feb 2024)	Standard Price
END-USERS				
Company Profiles: Biopharma, BIG Pharmas, CMO's, Europe Academic & Research Institutes Applicable Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations				
2 Day Main Conference only [GBP]	1050	1250	1450	1650
Service/Solution Providers				
Company Profiles: Service & Solution Providers, Europe/UK and International biopharma, Big Pharma, CDMO's, Academics and Research Institutes*. Applicable Job Profiles: Business Development, Marketing & Sales.				
2 Day Main Conference only [GBP]	2250	2450	2650	2850

EVENT VENUE

Copenhagen, Denmark



6th - 7th March 2024
Copenhagen, Denmark

BRING YOUR TEAM
*Buy 2, Get 3 passes
*Buy 3, Get 5 passes

2 Day pass to the Biologics World Nordics 2024

This offer is limited to professionals in the "BUYER" profile working in the fields of Manufacturing, External Manufacturing, Head of CMO, Head of Quality, Facility Head, Supply Chain in Big Pharmas, International/European Biopharmas, CMOs, and Academic & Research Institutes.

INNER CIRCLE: Speaker referrals and professionals who are buyers working in the same organization as our speakers are entitled for a 15% discount

Group Discount for Solution Providers & General Public: Buy 3 and get 10% off, Buy 5 get 20% off, Buy 6 and above, get 25% off

3 Easy Ways to Register:

1. Online
To book online, please visit:
<https://imapac.com/biologicsworldnordics/>

2. Telephone
To register over the phone, please call us on
+65 8198 7947

3. Mail
By cheque made payable to:
IMAPAC PTE. LTD.
Send with this booking form to:

IMAPAC PTE. LTD.
133 Cecil Street, #05-02A Keck Seng Tower, Singapore 069535

Group Booking

Send your team & save more!

3 delegates **SAVE 10%**

5 delegates **SAVE 20%**

Call **+65 3109 0127**

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____

By signing and returning this form, you are accepting our terms and conditions.

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay Credit Card Non-credit card and add US\$100 bank handling fee

Online credit card payment:

Please register at: <https://imapac.com/biologicsworldnordics/#ticket-on-sale-now-1>

Visa MasterCard American Express

Name on Card _____ Card Number _____

Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

Bank transfer: Payment by bank transfer must quote delegate name and conference name.

For bank details & swift code, it will be emailed to you as part of the invoice.

Cheque payment: Crossed cheque payable to IMAPAC Pte Ltd, and mail it in a sealed envelope to **IMAPAC Pte Ltd, 133 Cecil Street, #05-02A Keck Seng Tower, Singapore 069535**

TERMS & CONDITIONS:

- Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice.
- Registration will not be confirmed until full payment has been received.
- Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you.
- The registration fee includes refreshments, lunches, cocktails and full conference documentation. The conference fee does not include hotel accommodation.
- Staff at the event will request a credit card guarantee for delegates without proof of payment.

CANCELLATION & SUBSTITUTION POLICY:

- Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit note to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
- A substitution from the same organisation can be made at any time in writing at no extra charge.
- In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference or in the event of postponement by IMAPAC, towards the rescheduled date.

CHANGES TO CONFERENCE & AGENDA:

IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Control to alter the content and timing of the programme, venue or the identity of the speakers without any liability to the delegates. Changes to the agenda will be updated on our website as soon as possible.

DATA PROTECTION: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.



ASIA PACIFIC EVENTS

2024

January

14th Edition
VACCINES
WORLD SUMMIT 2024

Hyderabad

23-24 January 2024

3rd ANNUAL
BIOLOGICS
FESTIVAL INDIA
2024

Hyderabad

23-24 January 2024

February

AUSTRALIA
BIOLOGICS
FESTIVAL 2024

Melbourne, Australia

20-21 Feb 2024

March

THE 11TH ANNUAL
BIOLOGICS
MANUFACTURING ASIA 2024

MBS, Singapore

20-21 March 2024

2ND ANNUAL
CLINICAL TRIALS
FESTIVAL 2024

MBS, Singapore

20-21 March 2024

8th Edition
BIOLOGISTICS
WORLD ASIA 2024

MBS, Singapore

20-21 March 2024

August

13th Edition
BIOLOGICS
MANUFACTURING
KOREA 2024

Incheon, Korea

13 - 14 August 2024

6th Edition
VACCINE WORLD
EAST ASIA CONGRESS 2024

Incheon, Korea

13 - 14 August 2024

September

8th Edition
CELL & GENE THERAPY
WORLD ASIA 2024

Singapore

11 - 12 September 2024

CRYOGENIC
LOGISTICS
WORLD ASIA 2024

Singapore

11 - 12 September 2024

3rd Edition
BIOLOGICS
CONTRACT MANUFACTURING
ASIA 2024

Singapore

11 - 12 September 2024

6th Edition
VACCINE
WORLD ASIA CONGRESS 2024

Singapore

11 - 12 September 2024

Biologics
Digitalization & AI
World 2024

Singapore

11 - 12 September 2024

October

12th Edition
BIOLOGICS
WORLD
TAIWAN 2024

Taipei, Taiwan

23 - 24 October 2024

4th Edition
STEM CELLS
& REGENERATIVE
MEDICINE ASIA 2024

Taipei, Taiwan

23 - 24 October 2024

MICROBIOME
WORLD ASIA 2024

Taipei, Taiwan

23 - 24 October 2024



IMAPAC
IMAGINE YOUR IMPACT

IMAPAC Calendar of Events

ASIA PACIFIC EVENTS

2025

January

15th Edition
VACCINES
WORLD SUMMIT 2025

Hyderabad

22-23 Jan 2025



Hyderabad

22-23 Jan 2025

February

AUSTRALIA
BIOLOGICS
FESTIVAL 2025

Melbourne, Australia

5 - 6 February 2025

March

THE 12th ANNUAL
BIOLOGICS
MANUFACTURING ASIA 2025

Singapore

19 - 20 March 2025



Singapore

19 - 20 March 2025

9th Edition
BIOLOGISTICS
WORLD ASIA 2025

Singapore

19 - 20 March 2025



Singapore

19 - 20 March 2025



EUROPE EVENTS

2024

February



Part of Biologics Manufacturing World Series
London, UK

20-21 Feb 2024



Part of Biologics Manufacturing World Series
Dublin, Ireland

28 - 29 February 2024

March



Copenhagen, Denmark

6 - 7 March 2024

June



Part of Cell & Gene Therapy World Series
London, UK

11 - 12 June 2024



London, UK

11 - 12 June 2024

2025

January



Part of Biologics Manufacturing World Series
London, UK

22 - 23 Jan 2025

February



Part of Biologics Manufacturing World Series
Dublin, Ireland

25 - 26 Feb 2025

March



Part of Clinical Trial Series
London, UK

4 - 5 March 2025



Part of Biologistic World Series
London, UK

4 - 5 March 2025



IMAPAC
IMAGINE YOUR IMPACT

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS

B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events

"Create an engaging experience for your audiences, explore our B2B Events Solutions."

[LEARN MORE](#)

360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

"Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector."

[LEARN MORE](#)

DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

"**Customize the dashboard based on your needs.** Drill down to the data you need using custom views."

[LEARN MORE](#)

CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

"With access to a database of **60,000+ life science professionals**. We conduct research with a highly -qualified audience."

[LEARN MORE](#)

REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[LEARN MORE](#)



IMAPAC
IMAGINE YOUR IMPACT

Helping the Global Biopharmaceutical Industry Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

